- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00232206
Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer
A Phase II Study of Cisplatin Plus Docetaxel as Neoadjuvant Therapy for Stages IB Through Selected IIIA NSCLC
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Non-small cell lung cancer (NSCLC) accounts for 80% of new lung cancer diagnoses in the US. Surgery is the primary most successful treatment for early stage patients. However, even lung cancers caught at an early stage (stage IB through selected IIIA) have 5 year survivals after surgery at a rate of only 10-60%. Postoperative platinum based chemotherapy offers a 4-15% survival benefit, depending on stage in fit patients after complete surgical removal of early stage disease. Preoperative platinum based chemotherapy has been shown in small randomized trials to benefit patients with stage IIIA, N2 positive disease, but is not standard of care in earlier stage disease, such as the population in this study.
The combination of cisplatin and docetaxel is approved in the US for front line therapy of stage IV NSCLC based on randomized clinical data showing efficacy and manageable toxicity. Given the efficacy and tolerance of this combination in the metastatic setting, this regimen is an obvious choice for study in the neoadjuvant setting.
PET imaging is approved in the US for determining size, site and spread of lung cancer (staging) and has been shown to reduce unnecessary surgery when used as part of preoperative evaluation. Because NSCLC is not 100% responsive to chemotherapy and CT scans may not show a change in tumor size until after several cycles of chemotherapy, PET imaging might be an effective way to provide an earlier and more reliable estimate of response.
Preoperative chemotherapy will be given for a total of two cycles 21 days apart if any adverse events have resolved and there is no evidence of disease progression. Patients will undergo CT chest through liver and PET scans for restaging following the second cycle and will then be scheduled for surgery 3-6 weeks after the second cycle of chemotherapy. Patients who have responded according to CT and/or PET imaging, or surgical pathology will go on to receive an additional two cycles of chemotherapy with docetaxel and cisplatin once the patient has recovered from surgery.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97213
- Providence Portland Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically or cytologically confirmed NSCLC appropriate for surgery
- Medically fit for resection by lobectomy or pneumonectomy
- T1-2N1 disease by CT must have negative N2/N3 nodes by PET
- T3N1 disease must have pathologically negative N2/N3 nodes
- Measurable disease
- Patients must not be receiving other investigational therapy
- Prior surgery for NSCLC okay if resected > or = 5 years prior
- No prior chemotherapy or radiation for NSCLC
- No uncontrolled medical problems
- No factors that would preclude obtaining informed consent
- Age 18 or greater
- Performance status (PS) 0-1
- Peripheral neuropathy must be < grade 1
- Acceptable hematologic and chemistry parameters
- Renal: creatinine clearance (calculated) > 50 cc/min
Exclusion Criteria:
- History of severe hypersensitivity to docetaxel or like drugs
- Pregnant or nursing women
- Prior chemotherapy or radiation for NSCLC
- Symptomatic superior sulcus tumors
- Prior malignancy except for treated non-melanoma skin cancer, in situ cervical cancer, localized prostate cancer or cancer from which the patient has been disease free for greater than three years
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
---|
Primary objective: To assess the pathologic complete and partial response rate to neoadjuvant treatment with two cycles of cisplatin and docetaxel chemotherapy prior to resection of early stage NSCLC
|
Sekundære resultatmål
Resultatmål |
---|
Secondary objectives: Assessment of radiographic response rate by CT scanning, overall survival, time to progression, rate of complete surgical resection and toxicity
|
Evaluation of the predictive power of PET to define pathologic response
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Brendan Curti, MD, Director, Lung Research
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Luftvejssygdomme
- Neoplasmer
- Lungesygdomme
- Neoplasmer efter sted
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Lungeneoplasmer
- Karcinom, ikke-småcellet lunge
- Molekylære mekanismer for farmakologisk virkning
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitose modulatorer
- Docetaxel
Andre undersøgelses-id-numre
- PPMC-EACRI-IRB-05-032
- IIT #12207
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Ikke-småcellet lungekarcinom
-
AHS Cancer Control AlbertaCross Cancer InstituteAfsluttetOmfattende Stage Small Cel Lung CancerCanada
-
Universitaire Ziekenhuizen KU LeuvenUkendtLymfom | Hodgkin lymfom | Non-Hodgkin lymfom (follikulært, diffust B-cel lymfom, PTLD og Mantle Cel lymfom)Belgien
-
National Cancer Institute (NCI)AfsluttetIldfast malignt fast neoplasma | Tilbagevendende malignt fast neoplasma | Metastatisk malignt fast neoplasma | Uoprettelig fast neoplasma | Tilbagevendende småcellet lungekarcinom | Stadie IIIA Lunge småcellet karcinom AJCC v7 | Stadie IIIB Lunge småcellet karcinom AJCC v7 | Stadie IV lunge småcellet... og andre forholdForenede Stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeSezary syndrom | Refraktær T-celle non-Hodgkin lymfom | Merkel cellekarcinom | Anaplastisk storcellet lymfom, ALK-positivt | Ekstramammær Paget sygdom | Tilbagevendende T-celle non-Hodgkin lymfom | Tilbagevendende moden T-celle og NK-celle non-Hodgkin lymfom | Refraktær moden T-celle og NK-celle non-Hodgkin... og andre forholdForenede Stater
Kliniske forsøg med Neoadjuvant Therapy with Cisplatin Plus Docetaxel
-
Hospital of Stomatology, Wuhan UniversityJiangsu HengRui Medicine Co., Ltd.RekrutteringOralt planocellulært karcinomKina
-
Optimal Health ResearchAfsluttetBrystkræft | Lungekræft | ProstatakræftForenede Stater
-
University of ChicagoAfsluttetIkke-småcellet lungekræftForenede Stater
-
Mei ShiUkendtLivmoderhalskræft | Toksicitet på grund af strålebehandlingKina
-
Samsung Medical CenterAktiv, ikke rekrutterendeSpytkirtelkræftKorea, Republikken
-
Huai'an First People's HospitalThe Second People's Hospital of Huai'an; lian shui county People's Hospital og andre samarbejdspartnereAfsluttetEsophageal pladecellekarcinomKina
-
Samsung Medical CenterSanofiAfsluttetKarcinom, ikke-småcellet lungeKorea, Republikken
-
Shanghai Ninth People's Hospital Affiliated to...RekrutteringOralt planocellulært karcinomKina
-
Shanghai Jiao Tong University School of MedicineShanghai 10th People's Hospital; Jiangxi Provincial Cancer Hospital; Shanghai... og andre samarbejdspartnereRekrutteringTilbagevendende ikke-småcellet lungekræftKina
-
Zhejiang Cancer HospitalWenzhou Medical University; Second Affiliated Hospital, School of Medicine... og andre samarbejdspartnereUkendtNasopharyngealt karcinom | KemoradiationKina